BACKGROUND: Direct comparisons of similar doses of a novel influenza virus antigen administered by the intradermal route and the intramuscular route have not been reported. METHODS: A total of 227 healthy adults aged 18-49 years were randomized to receive 2 doses 1 month apart of a subvirion inactivated influenza A virus subtype H5N1 (rgA/Vietnam/1203/2004) vaccine containing 38.7 μg of H5N1 hemagglutinin (HA), by the intramuscular route or by the intradermal route using the Mantoux technique. Clinical and serologic responses were assessed. RESULTS:Injection site reactions were more frequent in the intradermal group. Immune responses and the geometric mean titer of serum hemagglutination inhibition and neutralizing antibodies 1 month after receipt of the first dose were similar and low but were significantly higher after 2 doses of vaccine in both groups. CONCLUSIONS: Intramuscular and intradermal delivery of vaccine were both well tolerated. Immune responses after 2 doses of this influenza A/H5N1 HA (38.7 μg) were low and not significantly different when given by the intradermal or intramuscular route. Evaluation of higher dosages, alternative intradermal delivery methods, and the addition of adjuvants will be needed to enhance the immunogenicity of inactivated influenza A/H5N1 vaccines by the intradermal route. CLINICAL TRIALS REGISTRATION: NCT00439335.
RCT Entities:
BACKGROUND: Direct comparisons of similar doses of a novel influenza virus antigen administered by the intradermal route and the intramuscular route have not been reported. METHODS: A total of 227 healthy adults aged 18-49 years were randomized to receive 2 doses 1 month apart of a subvirion inactivated influenza A virus subtype H5N1 (rgA/Vietnam/1203/2004) vaccine containing 38.7 μg of H5N1 hemagglutinin (HA), by the intramuscular route or by the intradermal route using the Mantoux technique. Clinical and serologic responses were assessed. RESULTS: Injection site reactions were more frequent in the intradermal group. Immune responses and the geometric mean titer of serum hemagglutination inhibition and neutralizing antibodies 1 month after receipt of the first dose were similar and low but were significantly higher after 2 doses of vaccine in both groups. CONCLUSIONS: Intramuscular and intradermal delivery of vaccine were both well tolerated. Immune responses after 2 doses of this influenzaA/H5N1 HA (38.7 μg) were low and not significantly different when given by the intradermal or intramuscular route. Evaluation of higher dosages, alternative intradermal delivery methods, and the addition of adjuvants will be needed to enhance the immunogenicity of inactivated influenzaA/H5N1 vaccines by the intradermal route. CLINICAL TRIALS REGISTRATION: NCT00439335.
Authors: Richard T Kenney; Sarah A Frech; Larry R Muenz; Christina P Villar; Gregory M Glenn Journal: N Engl J Med Date: 2004-11-03 Impact factor: 91.245
Authors: Robert B Belshe; Frances K Newman; Ken Wilkins; Irene L Graham; Elizabeth Babusis; Marian Ewell; Sharon E Frey Journal: Vaccine Date: 2007-07-26 Impact factor: 3.641
Authors: Robert Arnou; Giancarlo Icardi; Marijke De Decker; Arvydas Ambrozaitis; Marie-Pierre Kazek; Françoise Weber; Pierre Van Damme Journal: Vaccine Date: 2009-10-20 Impact factor: 3.641
Authors: Wendy A Keitel; Cornelia L Dekker; ChrisAnna Mink; James D Campbell; Kathryn M Edwards; Shital M Patel; Dora Y Ho; Helen K Talbot; Kuo Guo; Diana L Noah; Heather Hill Journal: Vaccine Date: 2009-03-25 Impact factor: 3.641
Authors: Rebecca C Brady; John J Treanor; Robert L Atmar; Wendy A Keitel; Robert Edelman; Wilbur H Chen; Patricia Winokur; Robert Belshe; Irene L Graham; Diana Lee Noah; Kuo Guo; Heather Hill Journal: Vaccine Date: 2009-07-03 Impact factor: 3.641
Authors: Innocent N Mbawuike; Robert L Atmar; Shital M Patel; David B Corry; Patricia L Winokur; Rebecca C Brady; Wilbur H Chen; Kathryn M Edwards; C Buddy Creech; Emmanuel B Walter; Sharon E Frey; Robert B Belshe; Johannes B Goll; Heather Hill; Wendy A Keitel Journal: Vaccine Date: 2015-12-04 Impact factor: 3.641
Authors: Daniel F Hoft; Kathleen Lottenbach; Johannes B Goll; Heather Hill; Patricia L Winokur; Shital M Patel; Rebecca C Brady; Wilbur H Chen; Kathryn Edwards; C Buddy Creech; Sharon E Frey; Tamara P Blevins; Rachelle Salomon; Robert B Belshe Journal: J Infect Dis Date: 2016-07-20 Impact factor: 5.226
Authors: Robert B Couch; William K Decker; Budi Utama; Robert L Atmar; Diane Niño; Jing Qi Feng; Matthew M Halpert; Gillian M Air Journal: PLoS One Date: 2012-12-11 Impact factor: 3.240
Authors: Jiong Wang; Dongmei Li; Sheldon Perry; Shannon P Hilchey; Alexander Wiltse; John J Treanor; Mark Y Sangster; Martin S Zand Journal: mBio Date: 2021-07-06 Impact factor: 7.867